Gene therapy for ADA-SCID: Defining the factors for successful outcome

Blood

Volumn 120, Issue 18, 2012, Pages 3628-3629

  Gaspar, H Bobby ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN;

ADENOSINE DEAMINASE DEFICIENCY; ADENOSINE DEAMINASE DEFICIENT SEVERE COMBINED IMMUNE DEFICIENCY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; ENZYME REPLACEMENT; GENE THERAPY; HUMAN; IMMUNE DEFICIENCY; LOW DRUG DOSE; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 84868576992     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-446559     Document Type: Note

References (15)

1. Carbonaro DA, Jin X, Wang X, et al. Gene therapy/ bone marrow transplant in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction. Blood. 2012;120(18):3677-3687.
2. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012;120(18):3635-3646.
3. Blaese RM, Culver KW, Miller AD, et al.Tlymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270(5235):475- 480.
4. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science. 1995;270 (5235):470-475.
5. Hoogerbrugge PM, van Beusechem VW, Fischer A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 1996;3(2):179-183. (Pubitemid 26117428)
6. Kohn DB, Hershfield MS, Carbonaro D, et al.Tlymphocytes with a normalADAgene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 1998;4(7):775-780. (Pubitemid 28331017)
7. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. NEngl J Med. 2009;360(5):447-458.
8. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to longterm immunological recovery and metabolic correction. Sci Transl Med. 2011;3(97):97ra80.
9. Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002; 8(5):423-425. (Pubitemid 34546725)
10. Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase deficient severe combined immunodeficiency [published online ahead of print July 12, 2012]. Blood. doi: 10.1182/blood-2011-12-396879.
11. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. NEngl J Med. 2003;348(3):255-256. (Pubitemid 36077924)
12. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2): 198-204.
13. Avedillo Díez I, Zychlinski D, Coci EG, et al. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm. 2011;8(5):1525-1537.
14. Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009; 17(11):1919-1928.
15. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24(6):687-696. (Pubitemid 43882120)